Related Experiment Video

Updated: Aug 24, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial

Anai E S Durazzo1, Fábio S Machado, Dimas T Ikeoka

  • 1Heart Institute and Vascular Surgery Department, University of São Paulo Medical School, São Paulo, Brazil. anaidurazzo@uol.com.br

Journal of Vascular Surgery
|April 28, 2004
PubMed

Insights

Short-term atorvastatin significantly reduces major adverse cardiovascular events after vascular surgery. This study found an 8% event rate with atorvastatin versus 26% with placebo over six months.

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Pharmacology

Background:

  • Cardiovascular complications are a leading cause of death after vascular surgery.
  • Statin therapy, like atorvastatin, may prevent cardiac events by stabilizing coronary plaques.

Purpose of the Study:

  • To evaluate the efficacy of atorvastatin in reducing cardiovascular events post-vascular surgery.
  • To compare the incidence of major adverse cardiovascular events between atorvastatin and placebo groups.

Main Methods:

  • A prospective, randomized, placebo-controlled, double-blind trial involving 100 patients.
  • Patients received 20 mg atorvastatin or placebo daily for 45 days before vascular surgery.
  • Cardiovascular events (cardiac death, myocardial infarction, unstable angina, stroke) were tracked for six months.

Main Results:

  • Atorvastatin (8.0%) significantly reduced cardiac events compared to placebo (26.0%; P = .031).
  • Event-free survival was significantly higher in the atorvastatin group (P = .018).
  • The risk of cardiac events was more than three times higher in the placebo group.

Conclusions:

  • Short-term atorvastatin treatment effectively lowers the incidence of major adverse cardiovascular events following vascular surgery.
  • Atorvastatin demonstrates a significant protective effect against perioperative cardiac complications.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...